Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-29T15:28:51.948Z Has data issue: false hasContentIssue false
  • English
  • Français

Induced depression during antiviral treatment in chronic hepatitis C

Published online by Cambridge University Press:  16 April 2020

R. Navines ,
J. Moreno ,
P. Castellví ,
D. Gimenez ,
E. Gómez ,
M. Valdés ,
R. Solà  and
R. Martín-Santos
R. Navines
Affiliation:
Department of Psychiatry, Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain
J. Moreno
Affiliation:
Department of Psychiatry, Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain
P. Castellví
Affiliation:
Department of Psychiatry, Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain Section of Hepatology, Hospital del Mar-IMIM, UAB, Barcelona, Spain
D. Gimenez
Affiliation:
Section of Hepatology, Hospital del Mar-IMIM, UAB, Barcelona, Spain
E. Gómez
Affiliation:
Department of Psychiatry, Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain
M. Valdés
Affiliation:
Department of Psychiatry, Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain
R. Solà
Affiliation:
Section of Hepatology, Hospital del Mar-IMIM, UAB, Barcelona, Spain
R. Martín-Santos
Affiliation:
Department of Psychiatry, Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The hepatitis C virus infection (HVC) represents a public health problem that affects the 3% of world population. The currently recommended treatment is Pegylated Interferon (PegIFN) alpha and Ribavirin (RBV) during 24 or 48 weeks. This treatment has been associated with high rates of neuropsychiatric side effects, mainly depression. Recent studies have documented impairment in health related quality of life (SF-36) in these patients.

Aims

To study the induced depression and quality of life of chronic HVC patients under antiviral treatment.

Methods

Three hundred seventeen consecutive HCV patients, who received PegIFN alpha and RBV, were assessed using the SCID interview for DSM-IV. Moreover, the PHQ, the HADS and the SF-36 were administered at baseline, 4, 12, 24, and/or 48 weeks of treatment.

Results

Two hundred twenty-four (64.7%) of patients were men, the mean (SD) age was 43.6 (10.6), and 130 (40.1%) had history of mood disorder. One-hundred eleven (41%) of the sample had a depressive disorder during the treatment. There was a significant difference in the total SF-36 score and in all subscales (p < 0.001). HADS subscale of depression was highly correlated with SF-36 total score (p < 0.001).

Conclusions

During the antiviral treatment, HVC patients had a higher incidence of induced depression. Both physical and mental component scores of SF-36 in induced depressed patients were significantly worse.

This study has been supported in part by Spanish grants: FIS E08/00268, Dra. Martín-Santos, and Dr. Solà.

Type
P02-67
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 662
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.